These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 30219819)

  • 1. MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.
    Yang F; Guo L; Cao Y; Li S; Li J; Liu M
    Med Sci Monit; 2018 Sep; 24():6506-6516. PubMed ID: 30219819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer.
    Zhang WY; Liu YJ; He Y; Chen P
    J Cell Physiol; 2019 Apr; 234(4):4302-4313. PubMed ID: 30221354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical Cancer.
    Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
    Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hsa_circ_0000392 affects the radiation sensitivity of cervical cancer by targeting the miR-145-5p/CRKL/MAPK pathway].
    Tian J; Wang N; Wang C; Wu DP; Wang CH; Ding XJ; Wang YK
    Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):879-891. PubMed ID: 37875424
    [No Abstract]   [Full Text] [Related]  

  • 5. Regulation of p53 expression and apoptosis by vault RNA2-1-5p in cervical cancer cells.
    Kong L; Hao Q; Wang Y; Zhou P; Zou B; Zhang YX
    Oncotarget; 2015 Sep; 6(29):28371-88. PubMed ID: 26318295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1.
    Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y
    Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984
    [No Abstract]   [Full Text] [Related]  

  • 7. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
    Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
    Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor suppressor miRNA-204-5p promotes apoptosis by targeting BCL2 in prostate cancer cells.
    Lin YC; Lin JF; Tsai TF; Chou KY; Chen HE; Hwang TI
    Asian J Surg; 2017 Sep; 40(5):396-406. PubMed ID: 27519795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-125a-5p modulates human cervical carcinoma proliferation and migration by targeting ABL2.
    Qin X; Wan Y; Wang S; Xue M
    Drug Des Devel Ther; 2016; 10():71-9. PubMed ID: 26766902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9.
    Wang J; Xue X; Hong H; Qin M; Zhou J; Sun Q; Liang H; Gao L
    Oncotarget; 2017 Jan; 8(1):574-582. PubMed ID: 27880941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2.
    Tung MC; Lin PL; Cheng YW; Wu DW; Yeh SD; Chen CY; Lee H
    Oncotarget; 2016 May; 7(22):32362-74. PubMed ID: 27083050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-182-5p regulates BCL2L12 and BCL2 expression in acute myeloid leukemia as a potential therapeutic target.
    Zhang S; Zhang Q; Shi G; Yin J
    Biomed Pharmacother; 2018 Jan; 97():1189-1194. PubMed ID: 29136958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-box transcription factor TBX1, targeted by microRNA-6727-5p, inhibits cell growth and enhances cisplatin chemosensitivity of cervical cancer cells through AKT and MAPK pathways.
    Liu H; Song M; Sun X; Zhang X; Miao H; Wang Y
    Bioengineered; 2021 Dec; 12(1):565-577. PubMed ID: 33557670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-144 reverses cisplatin resistance in cervical cancer via targeting LHX2.
    Shi F; Su J; Liu Z; Wang J; Wang T
    J Cell Biochem; 2019 Sep; 120(9):15018-15026. PubMed ID: 31017720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knock-down of NDRG2 sensitizes cervical cancer Hela cells to cisplatin through suppressing Bcl-2 expression.
    Liu J; Yang L; Zhang J; Zhang J; Chen Y; Li K; Li Y; Li Y; Yao L; Guo G
    BMC Cancer; 2012 Aug; 12():370. PubMed ID: 22920753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-101-5p inhibits the growth and metastasis of cervical cancer cell by inhibiting CXCL6.
    Shen W; Xie XY; Liu MR; Wang LL
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):1957-1968. PubMed ID: 30915738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosome-delivered circRNA circSYT15 contributes to cisplatin resistance in cervical cancer cells through the miR-503-5p/RSF1 axis.
    Chen Z; Xu Z; Wang Q; Wang L; Zhang H; Wang W; Zhao H; Guo Y; Cui J
    Cell Cycle; 2023 Oct; 22(20):2211-2228. PubMed ID: 37974391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer.
    Tian J; Cheng L; Kong E; Gu W; Jiang Y; Hao Q; Kong B; Sun L
    Reprod Biol Endocrinol; 2022 Sep; 20(1):132. PubMed ID: 36056431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Probing the Effects of Retinoblastoma Binding Protein 6 (RBBP6) Knockdown on the Sensitivity of Cisplatin in Cervical Cancer Cells.
    Mehta H; Ambele MA; Mokgautsi N; Moela P
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.